Loading...

Cue Biopharma

DB:1UC
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1UC
DB
$175M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Cue Biopharma has significant price volatility in the past 3 months.
1UC Share Price and Events
7 Day Returns
-4%
DB:1UC
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-
DB:1UC
-7.4%
DE Biotechs
-5.6%
DE Market
1UC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cue Biopharma (1UC) -4% 6.8% 62.6% - - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • No trading data on 1UC.
  • No trading data on 1UC.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

1UC Value

 Is Cue Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cue Biopharma. This is due to cash flow or dividend data being unavailable. The share price is €7.367.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cue Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cue Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1UC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.94
NasdaqCM:CUE Share Price ** NasdaqCM (2019-04-24) in USD $8.45
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cue Biopharma.

DB:1UC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CUE Share Price ÷ EPS (both in USD)

= 8.45 ÷ -1.94

-4.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cue Biopharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cue Biopharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cue Biopharma's expected growth come at a high price?
Raw Data
DB:1UC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cue Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cue Biopharma's assets?
Raw Data
DB:1UC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.64
NasdaqCM:CUE Share Price * NasdaqCM (2019-04-24) in USD $8.45
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1UC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CUE Share Price ÷ Book Value per Share (both in USD)

= 8.45 ÷ 1.64

5.15x

* Primary Listing of Cue Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cue Biopharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cue Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cue Biopharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1UC Future Performance

 How is Cue Biopharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-67.8%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Cue Biopharma expected to grow at an attractive rate?
  • Unable to compare Cue Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cue Biopharma's earnings growth to the Germany market average as no estimate data is available.
  • Cue Biopharma's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1UC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1UC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -67.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1UC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1UC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -51 1
2022-12-31 0 -38 1
2021-12-31 0 -38 1
2020-12-31 0 -29 1
2019-12-31 1 -25 1
DB:1UC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -26 -39
2018-09-30 1 -24 -38
2018-06-30 0 -22 -30
2018-03-31 -18 -27
2017-12-31 -12 -23
2017-09-30 -12 -16
2017-06-30 -10 -13
2017-03-31 -8 -10
2016-12-31 -6 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cue Biopharma is high growth as no earnings estimate data is available.
  • Cue Biopharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1UC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cue Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1UC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
DB:1UC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.94
2018-09-30 -2.12
2018-06-30 -1.96
2018-03-31 -2.09
2017-12-31 -2.16
2017-09-30 -1.58
2017-06-30 -1.39
2017-03-31 -1.16
2016-12-31 -1.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cue Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cue Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cue Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1UC Past Performance

  How has Cue Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cue Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cue Biopharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Cue Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cue Biopharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cue Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cue Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1UC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.14 -38.98 14.14
2018-09-30 0.81 -37.80 9.97 17.17
2018-06-30 0.36 -30.28 8.11 17.17
2018-03-31 -27.41 7.01 20.39
2017-12-31 -23.23 6.06
2017-09-30 -15.64 3.96 1.79
2017-06-30 -12.63 3.92 2.83
2017-03-31 -9.61 3.75 5.86
2016-12-31 -7.66 2.82 4.84
2015-12-31 -1.93 0.74 1.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cue Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cue Biopharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cue Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cue Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cue Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1UC Health

 How is Cue Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cue Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cue Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cue Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cue Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cue Biopharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cue Biopharma Company Filings, last reported 3 months ago.

DB:1UC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 33.97 0.00 39.21
2018-09-30 39.40 0.00 39.18
2018-06-30 49.23 0.00 45.74
2018-03-31 55.24 0.00 53.66
2017-12-31 61.61 0.00 63.76
2017-09-30 4.38 0.00 3.45
2017-06-30 8.66 0.00 7.36
2017-03-31 15.17 0.00 14.98
2016-12-31 15.17 0.00 14.98
2015-12-31 6.94 0.00 6.46
  • Cue Biopharma has no debt.
  • Cue Biopharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cue Biopharma has sufficient cash runway for 1.4 years based on current free cash flow.
  • Cue Biopharma has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 60% each year.
X
Financial health checks
We assess Cue Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cue Biopharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1UC Dividends

 What is Cue Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cue Biopharma dividends.
If you bought €2,000 of Cue Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cue Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cue Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1UC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1UC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cue Biopharma has not reported any payouts.
  • Unable to verify if Cue Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cue Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cue Biopharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cue Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cue Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cue Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1UC Management

 What is the CEO of Cue Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dan Passeri
COMPENSATION $410,371
AGE 57
TENURE AS CEO 2.7 years
CEO Bio

Mr. Daniel R. Passeri, also known as Dan, MSc., J.D. has been the Chief Executive Officer and President of Cue Biopharma, Inc. since August 2016. Mr. Passeri joined Cue Biopharma in August 2016. Mr. Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on behalf of publicly traded companies, with deep experience in both oncology and strategic partnership generation. has been Consultant of Curis, Inc. since September 14, 2016. Mr. Passeri served as Strategic Advisor of Curis, Inc. from June 3, 2014 to September 14, 2016. Mr. Passeri served as the Chief Executive Officer of Curis, Inc. from September 2001 to June 2, 2014 and served as its President from September 2001 to February 2013. From December 2014 to June 2015, Mr. Passeri served as Chief Officer of Technology Management and Business Development of the Jackson Laboratory for Genomic Medicine. Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of Curis Inc., from November 2000 to September 2001. From March 1997 to November 2000, he was employed by GeneLogic Inc., as Senior Vice President of Corporate Development and Strategic Planning. From February 1995 to March 1997, he was employed by Boehringer Mannheim as Director of Technology Management. He served as Vice Chairman of Curis, Inc. from June 2, 2014 to September 14, 2016. He has been a Director of Cue Biopharma, Inc. since 2016. Mr. Passeri served as a Director of Curis, Inc. from September 2001 to September 14, 2016. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in biology from Northeastern University.

CEO Compensation
  • Dan's compensation has been consistent with company performance over the past year.
  • Dan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cue Biopharma management team in years:

1.1
Average Tenure
53
Average Age
  • The average tenure for the Cue Biopharma management team is less than 2 years, this suggests a new team.
Management Team

Dan Passeri

TITLE
CEO, President & Director
COMPENSATION
$410K
AGE
57
TENURE
2.7 yrs

Colin Sandercock

TITLE
Senior VP
COMPENSATION
$1M
AGE
61
TENURE
1.3 yrs

Ron Seidel

TITLE
Executive VP and Head of Research & Development
COMPENSATION
$317K
AGE
42

Rodolfo Chaparro

TITLE
Executive VP & Head of Immunology
COMPENSATION
$317K
AGE
45

Steven Almo

TITLE
Co-Founder and Chairman of Scientific & Clinical Advisory Board
AGE
57

Kerri-Ann Millar

TITLE
VP of Finance and Principal Accounting & Finance Officer
AGE
49
TENURE
0.9 yrs

Anish Suri

TITLE
Senior VP & Chief Scientific Officer
AGE
45
TENURE
0.9 yrs

Bethany Mancilla

TITLE
Chief Business Officer and Senior VP of Corporate Development & Strategic Planning
TENURE
0.8 yrs

Ken Pienta

TITLE
Acting Chief Medical Officer
AGE
58
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Cue Biopharma board of directors in years:

3.5
Average Tenure
57
Average Age
  • The tenure for the Cue Biopharma board of directors is about average.
Board of Directors

Peter Kiener

TITLE
Chairman of the Board
COMPENSATION
$372K
AGE
66

Dan Passeri

TITLE
CEO, President & Director
COMPENSATION
$410K
AGE
57
TENURE
3.3 yrs

Steven Almo

TITLE
Co-Founder and Chairman of Scientific & Clinical Advisory Board
AGE
57
TENURE
4.3 yrs

Barry Simon

TITLE
Director
COMPENSATION
$30K
AGE
53
TENURE
3.1 yrs

Steven McKnight

TITLE
Director
COMPENSATION
$30K
AGE
69
TENURE
3.1 yrs

Fred Driscoll

TITLE
Director
AGE
67
TENURE
0.8 yrs

Cameron Gray

TITLE
Director
AGE
47
TENURE
4.3 yrs

Christopher Marlett

TITLE
Director
AGE
53
TENURE
3.8 yrs

Anthony DiGiandomenico

TITLE
Director
AGE
52
TENURE
3.8 yrs

Hidde Ploegh

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jan 19 Buy Anthony DiGiandomenico Individual 24. Dec 18 24. Dec 18 10,000 €4.22 €42,164
02. Jan 19 Buy Christopher Marlett Individual 31. Dec 18 31. Dec 18 18,521 €4.05 €75,058
02. Jan 19 Buy Anthony DiGiandomenico Individual 28. Dec 18 28. Dec 18 7,000 €4.04 €28,252
28. Dec 18 Buy Anthony DiGiandomenico Individual 27. Dec 18 27. Dec 18 20,000 €4.18 €83,618
27. Dec 18 Buy Christopher Marlett Individual 26. Dec 18 26. Dec 18 19,647 €3.76 €73,876
26. Dec 18 Buy Christopher Marlett Individual 21. Dec 18 21. Dec 18 17,200 €3.97 €68,270
26. Dec 18 Buy Anish Suri Individual 21. Dec 18 21. Dec 18 2,000 €3.83 €7,658
26. Dec 18 Buy Anthony DiGiandomenico Individual 21. Dec 18 21. Dec 18 10,000 €3.93 €39,341
21. Dec 18 Buy Christopher Marlett Individual 20. Dec 18 20. Dec 18 9,438 €4.15 €39,184
20. Dec 18 Buy Christopher Marlett Individual 19. Dec 18 19. Dec 18 400 €4.38 €1,750
19. Dec 18 Buy Christopher Marlett Individual 18. Dec 18 18. Dec 18 3,664 €4.57 €16,763
18. Dec 18 Buy Anthony DiGiandomenico Individual 17. Dec 18 17. Dec 18 10,000 €4.83 €48,306
17. Dec 18 Buy Christopher Marlett Individual 13. Dec 18 13. Dec 18 10,000 €4.46 €44,563
13. Dec 18 Buy Christopher Marlett Individual 12. Dec 18 12. Dec 18 12,189 €4.48 €54,559
12. Dec 18 Buy Christopher Marlett Individual 11. Dec 18 11. Dec 18 7,543 €4.29 €32,374
29. Aug 18 Buy Kerri-Ann Millar Individual 29. Aug 18 29. Aug 18 1,000 €7.25 €7,250
20. Aug 18 Buy Daniel Passeri Individual 16. Aug 18 16. Aug 18 6,000 €7.10 €42,577
29. Jun 18 Buy Daniel Passeri Individual 29. Jun 18 29. Jun 18 1,600 €10.26 €16,415
X
Management checks
We assess Cue Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cue Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1UC News

Simply Wall St News

1UC Company Info

Description

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: Cue Biopharma, Inc.
1UC
Exchange: DB
Founded: 2014
$156,545,006
20,734,232
Website: http://www.cuebiopharma.com
Address: Cue Biopharma, Inc.
21 Erie Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CUE Common Stock Nasdaq Capital Market US USD 02. Jan 2018
DB 1UC Common Stock Deutsche Boerse AG DE EUR 02. Jan 2018
Number of employees
Current staff
Staff numbers
47
Cue Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:38
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/14
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.